Logo

New England Biolabs, TriLink Bio Ink Supply Agreement

Oct 07, 2014 | staff reporter

NEW YORK (GenomeWeb) — New England Biolabs will supply RNA synthesis reagents to TriLink Biotechnologies under an agreement announced by the companies today.

Specific terms of the agreement call for Ipswich, Mass.-based NEB to manufacture and supply enzymes for San Diego-based TriLink for in vitro transcription, capping, and poly(A) tailing of RNA.

"NEB is a leading supplier of molecular biology enzymes and associated reagents for life science research," TriLink President and CEO Richard Hogrefe said in a statement. "This agreement aligns NEB and TriLink in providing the market with the highest quality RNA for projects of all scales."

Filed under

PCR
Gene Editing, Gene Silencing, & CRISPR
Business News
supply agreement
RNAi
New England Biolabs
TriLink
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.